Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

M F Muldoon, S B Manuck, K A Matthews, M F Muldoon, S B Manuck, K A Matthews

Abstract

Objective: To determine the effects of lowering cholesterol concentrations on total and cause specific mortality in randomised primary prevention trials.

Design: Qualitative (meta-analytic) evaluation of total mortality from coronary heart disease, cancer, and causes not related to illness in six primary prevention trials of cholesterol reduction (mean duration of treatment 4.8 years).

Patients: 24,847 Male participants; mean age 47.5 years.

Main outcome measures: Total and cause specific mortalities.

Results: Follow up periods totalled 119,000 person years, during which 1147 deaths occurred. Mortality from coronary heart disease tended to be lower in men receiving interventions to reduce cholesterol concentrations compared with mortality in control subjects (p = 0.06), although total mortality was not affected by treatment. No consistent relation was found between reduction of cholesterol concentrations and mortality from cancer, but there was a significant increase in deaths not related to illness (deaths from accidents, suicide, or violence) in groups receiving treatment to lower cholesterol concentrations relative to controls (p = 0.004). When drug trials were analysed separately the treatment was found to reduce mortality from coronary heart disease significantly (p = 0.04).

Conclusions: The association between reduction of cholesterol concentrations and deaths not related to illness warrants further investigation. Additionally, the failure of cholesterol lowering to affect overall survival justifies a more cautious appraisal of the probable benefits of reducing cholesterol concentrations in the general population.

References

    1. Br J Psychiatry Suppl. 1989 Dec;(8):52-62
    1. Biol Psychiatry. 1984 Mar;19(3):435-9
    1. Arch Gen Psychiatry. 1989 Jul;46(7):604-6
    1. Control Clin Trials. 1986 Sep;7(3):177-88
    1. Biochem Pharmacol. 1985 Apr 1;34(7):1120-1
    1. J Chronic Dis. 1978 Jan;31(1):5-14
    1. Arch Intern Med. 1989 Jul;149(7):1589-91
    1. JAMA. 1972 Feb 14;219(7):845-51
    1. Life Sci. 1986 Mar 31;38(13):1185-92
    1. Acta Psychiatr Scand. 1985 Aug;72(2):155-60
    1. Neuropsychobiology. 1983;10(2-3):65-9
    1. Arteriosclerosis. 1989 Jan-Feb;9(1):129-35
    1. Int J Epidemiol. 1979 Jun;8(2):99-118
    1. J Am Coll Cardiol. 1986 Dec;8(6):1245-55
    1. Bull N Y Acad Med. 1968 Aug;44(8):936-49
    1. J Natl Cancer Inst. 1959 Apr;22(4):719-48
    1. Ann Intern Med. 1987 Apr;106(4):605-14
    1. N Engl J Med. 1987 Nov 12;317(20):1237-45
    1. Science. 1985 Jan 4;227(4682):40-1
    1. Psychosom Med. 1969 Mar-Apr;31(2):115-28
    1. Lancet. 1988 Oct 8;2(8615):839-41
    1. Pharmacol Biochem Behav. 1986 Jun;24(6):1775-7
    1. Soc Sci Med. 1982;16(22):1929-38
    1. Epidemiol Rev. 1984;6:192-216
    1. Prog Cardiovasc Dis. 1985 Mar-Apr;27(5):335-71
    1. J Am Coll Cardiol. 1988 Sep;12(3):814-7
    1. BMJ. 1989 Apr 8;298(6678):920-4
    1. Acta Psychiatr Scand. 1988 Nov;78(5):529-35
    1. Lancet. 1971 Mar 6;1(7697):464-7
    1. Neuropsychobiology. 1979;5(1):27-30
    1. Life Sci. 1986 May 12;38(19):1789-94

Source: PubMed

3
Subscribe